Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$68.22M$68.22M+33.4% vs Q3 2020 Net Income-$35.64M-$35.64MN/M vs Q3 2020 EPS Diluted-$0.59-$0.59N/M vs Q3 2020 Operating Income-$31,711,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$31,714,000+632.9% Margins · derivedOperating margin-46.5%−8.5 pt vs Q3 2020
Net margin-52.2%−8.2 pt vs Q3 2020
ended Sep 30, 2021 · filed Oct 29, 2021 · 29 d after period end